Prostate cancer (PCa) is the second most common cancer in men worldwide. A large
proportion of PCa are latent, never destined to progress or affect the patients' life. It is of …

Prostate specific antigen (PSA) remains the most used biomarker in the management of
early prostate cancer (PCa), in spite of the problems related to false positive results and …

Background The prostate-specific antigen (PSA) test is used to screen for prostate cancer
but has a high false-positive rate that translates into unnecessary prostate biopsies and …

Purpose: We evaluated the ability of PHI to discriminate aggressive prostate cancer from
indolent or no cancer in a biopsy naïve population. Materials and Methods: Two …

Simple Summary In the last decades, the widespread use of PSA as the standard tool for
prostate cancer diagnosis led to a high rate of overdiagnosis and overtreatment. More …

Prostate cancer (PC) is the second most common form of cancer in men worldwide.
Biomarkers have emerged as essential tools for treatment and assessment since the …

Prostate cancer remains the most commonly diagnosed noncutaneous malignancy among
Canadian men and is the third leading cause of cancer-related death. In 2016, an estimated …

Background There is no single definitive test to identify prostate cancer in men. Biopsies are
commonly used to obtain samples of prostate tissue for histopathological examination …

Background: Widespread use of prostate specific antigen (PSA) in screening procedures
allowed early identification of an increasing number of prostate cancers (PCas), mainly …

Purpose The association between exposure to testosterone replacement therapy (TRT) and
prostate cancer risk is controversial. The objective was to examine this association through …